The first Harvard Institute of Translational Immunology (HITI)/Helmsley Trust Pilot Grant RFA – focused on type 1 diabetes – is now available

Posted November 18, 2010

The Request for Applications (RFA) for the first Harvard Institute of Translational Immunology (HITI)/Helmsley Trust Pilot Grants in type 1 diabetes is now available on the Harvard Catalyst website.

Applications will be accepted once the application webform becomes available on December 2, 2010, and will be due on January 26, 2011 at 12:00 noon ET.

Any investigator with a Harvard faculty appointment, regardless of degree or institutional affiliation, is eligible to apply for these one-year, $50,000 to $200,000 grants.

This new funding opportunity is inspired by the winners of the Harvard Catalyst/InnoCentive Ideation Challenge, “What do we not know about type 1 diabetes.” Projects that address the five research areas identified through the Challenge will be given strong preference in the review process. The general topic areas are listed below (please see the RFA for full topic description):

1.     Discovering inciting autoantigens in T1D and evaluating the local inflammatory response

2.     Creating novel approaches to therapeutics delivery for T1D

3.     Developing novel monitoring devices

4.     Identifying environmental and microbial contributions to T1D

5.     Detecting biomarkers that are predictive of diagnosis, prognosis and response to therapy

For complete information about this opportunity, review the RFA.

HITI is a newly-established collaborative effort – recently announced by HMS Dean Jeffrey Flier, MD  – which will bring together basic, translational, and clinical investigators from across the Harvard community to develop interdisciplinary approaches for elucidating mechanisms of immune-mediated diseases.

Established in 1999, the Leona M. and Harry B. Helmsley Charitable Trust continues Mr. and Mrs. Helmsley’s remarkable philanthropic legacy. The Trust supports a broad spectrum of healthcare and medical research-based programs, including innovative and collaborative funding for research on T1D.